Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae)

Antiviral Res. 2018 Jan;149:75-77. doi: 10.1016/j.antiviral.2017.11.011. Epub 2017 Nov 15.


Parechovirus A3 (Par-A3, formerly human parechovirus 3) is an emerging viral infection of the central nervous system in children. We used an automated, homogeneous, cell based assay to identify itraconazole and posaconazole as inhibitors of Par-A3, with antiviral activity below concentrations clinically attainable in pediatric patients. Currently, there is no approved antiviral treatment for Par-A3 infection, despite numerous reports of serious Par-A3 disease in neonates and infants.

MeSH terms

  • Animals
  • Antifungal Agents / pharmacology
  • Antiviral Agents / pharmacology*
  • Cell Line
  • Cells, Cultured
  • Cytopathogenic Effect, Viral / drug effects
  • Dose-Response Relationship, Drug
  • Humans
  • Itraconazole / pharmacology*
  • Parechovirus / drug effects*
  • Picornaviridae Infections / virology
  • Triazoles / pharmacology*


  • Antifungal Agents
  • Antiviral Agents
  • Triazoles
  • Itraconazole
  • posaconazole